{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T11:20:40Z","timestamp":1778412040575,"version":"3.51.4"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81950410639"],"award-info":[{"award-number":["81950410639"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Multiple SARS-CoV-2 variants are still rampant across the United States (US). We aimed to evaluate the impact of vaccination scale-up and potential reduction in the vaccination effectiveness on the COVID-19 epidemic and social restoration in the US.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    We extended a published compartmental model and calibrated the model to the latest US COVID-19 data. We estimated the vaccine effectiveness against the variant and evaluated the impact of a potential reduction in vaccine effectiveness on the epidemics. We explored the epidemic trends under different levels of social restoration.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    We estimated the overall existing vaccine effectiveness against the variant as 88.5% (95% CI: 87.4\u201389.5%) with the vaccination coverage of 70% by the end of August, 2021. With this vaccine effectiveness and coverage, there would be 498,972 (109,998\u2013885,947) cumulative infections and 15,443 (3,828\u201327,057) deaths nationwide over the next 12 months, of which 95.0% infections and 93.3% deaths were caused by the variant. Complete social restoration at 60, 65, 70% vaccination coverage would increase cumulative infections to 1.6 (0.2\u20132.9) million 0.7 (0.1\u20131.2) million, and 511,159 (110,578\u2013911,740), respectively. At same time it would increase cumulative deaths to 39,040 (5,509\u201372,570), 19,562 (3,873\u201335,250), 15,739 (3,841\u201327,638), respectively. However, if the vaccine effectiveness were reduced to 75%, 50% or 25% due to new SARS-CoV-2 variants, there would be 667,075 (130,682\u20131,203,468), 1.7 (0.2\u20133.2) million, 19.0 (5.3\u201332.7) million new infections and 19,249 (4,281\u201334,217), 42,265 (5,081\u201379,448), 426,860 (117,229\u2013736,490) cumulative deaths to occur over the next 12 months. Further, social restoration at a lower vaccination coverage would lead to even greater secondary outbreaks.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Current COVID-19 vaccines remain effective against the SARS-CoV-2 variant, and 70% vaccination coverage would be sufficient to restore social activities to a pre-pandemic level. Further reduction in vaccine effectiveness against SARS-CoV-2 variants would result in a potential surge of the epidemic. Multiple measures, including public health interventions, vaccination scale-up and development of a new vaccine booster, should be integrated to counter the new challenges of new SARS-CoV-2 variants.\n                  <\/jats:p>","DOI":"10.3389\/fpubh.2021.801763","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:43:58Z","timestamp":1641775438000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Evaluating the Impact of SARS-CoV-2 Variants on the COVID-19 Epidemic and Social Restoration in the United States: A Mathematical Modelling Study"],"prefix":"10.3389","volume":"9","author":[{"given":"Rui","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoru","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guihua","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingwang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"key":"B1","unstructured":"2021"},{"key":"B2","unstructured":"2021"},{"key":"B3","unstructured":"2021"},{"key":"B4","unstructured":"2021"},{"key":"B5","unstructured":"2021"},{"key":"B6","unstructured":"2021"},{"key":"B7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.chom.2021.02.020","article-title":"The variant gambit: COVID-19's next move","volume":"29","author":"Plante","year":"2021","journal-title":"Cell Host Microbe"},{"key":"B8","doi-asserted-by":"publisher","first-page":"eabg3055","DOI":"10.1126\/science.abg3055","article-title":"Estimated transmissibility and impact of SARS-CoV-2 lineage B","volume":"372","author":"Davies","year":"2021","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/j.jinf.2021.05.008","article-title":"Mortality risk in patients infected with SARS-CoV-2 of the lineage B","volume":"83","author":"Kow","year":"2021","journal-title":"J Infect"},{"key":"B10","doi-asserted-by":"publisher","first-page":"P1351","DOI":"10.1016\/S0140-6736(21)00628-0","article-title":"Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012\/01 (B","volume":"397","author":"Emary","year":"2021","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1056\/NEJMc2102017","article-title":"Neutralizing activity of BNT162b2-elicited serum","volume":"384","author":"Liu","year":"2021","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1101\/2021.01.25.428137","article-title":"Antibody resistance of SARS-CoV-2 variants B","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","first-page":"100264","DOI":"10.1016\/j.xcrm.2021.100264","article-title":"BNT162b2 Vaccination effectively prevents the rapid rise of SARS-CoV-2 variant B.1.1.7 in high risk populations in Israel","volume":"2","author":"Munitz","year":"2021","journal-title":"Cell Rep Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41586-021-03412-7","article-title":"Sensitivity of SARS-CoV-2 B117 to mRNA vaccine-elicited antibodies","volume":"593","author":"Collier","year":"2021","journal-title":"Nature."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1056\/NEJMc2102179","article-title":"Serum neutralizing activity elicited by mRNA-1273 vaccine","volume":"384","author":"Wu","year":"2021","journal-title":"N Engl J Med."},{"key":"B16","unstructured":"2021"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med."},{"key":"B20","unstructured":"2020"},{"key":"B21","unstructured":"2021"},{"key":"B22","unstructured":"2021"},{"key":"B23","unstructured":"2021"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab079","article-title":"The impact of vaccination on COVID-19 outbreaks in the United States","author":"Moghadas","year":"2021","journal-title":"Clin Infect Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e0254456","DOI":"10.1371\/journal.pone.0254456","article-title":"The Impact of Vaccination to Control COVID-19 Burden in the United States: a Simulation Modeling Approach","volume":"16","author":"Alagoz","year":"2021","journal-title":"PLoS One"},{"key":"B26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3390\/vaccines9030223","article-title":"Epidemiological differences in the impact of COVID-19 vaccination in the United States and China","volume":"9","author":"Makhoul","year":"2021","journal-title":"Vaccines. (Basel)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/j.vaccine.2021.02.056","article-title":"Projected COVID-19 epidemic in the United States in the context of the effectiveness of a potential vaccine and implications for social distancing and face mask use","volume":"39","author":"Shen","year":"2021","journal-title":"Vaccine."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e06812","DOI":"10.1016\/j.heliyon.2021.e06812","article-title":"Stability analysis of SEIR model related to efficiency of vaccines for COVID-19 situation","volume":"7","author":"Wintachai","year":"2021","journal-title":"Heliyon."},{"key":"B29","doi-asserted-by":"publisher","first-page":"100865","DOI":"10.1016\/j.eclinm.2021.100865","article-title":"Accelerated vaccine rollout is imperative to mitigate highly transmissible COVID-19 variants","volume":"35","author":"Sah","year":"2021","journal-title":"EClinicalMedicine."},{"key":"B30","doi-asserted-by":"publisher","first-page":"719","DOI":"10.15585\/mmwr.mm7019e3","article-title":"Modeling of future COVID-19 cases, hospitalizations, and deaths, by vaccination rates and nonpharmaceutical intervention scenarios - United States, April-September 2021","volume":"70","author":"Borchering","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N Engl J Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1056\/NEJMc2036242","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"384","author":"Wang","year":"2021","journal-title":"N Engl J Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"071101","DOI":"10.1063\/5.0016240","article-title":"Forecasting the daily and cumulative number of cases for the COVID-19 pandemic in India. Chaos: an interdisciplinary","volume":"30","author":"Khajanchi","year":"2020","journal-title":"J Nonlinear Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"104285","DOI":"10.1016\/j.rinp.2021.104285","article-title":"Mathematical modeling of the COVID-19 pandemic with intervention strategies","volume":"25","author":"Khajanchi","year":"2021","journal-title":"Results Phys."},{"key":"B35","doi-asserted-by":"publisher","first-page":"84","DOI":"10.15302\/J-QB-020-0229","article-title":"Mathematical modeling and optimal intervention strategies of the COVID-19 outbreak","volume":"9","author":"Jayanta","year":"2021","journal-title":"Nonlinear Dyn."},{"key":"B36","doi-asserted-by":"publisher","first-page":"110173","DOI":"10.1016\/j.chaos.2020.110173","article-title":"A mathematical model for COVID-19 transmission dynamics with a case study of India","volume":"140","author":"Samui","year":"2020","journal-title":"Chaos Solitons Fractals."},{"key":"B37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11524-021-00517-2","article-title":"Effects of New York's executive order on face mask use on COVID-19 infections and mortality: a modeling study","volume":"98","author":"Shen","year":"2021","journal-title":"J Urban Health."},{"key":"B38","first-page":"100006","article-title":"What is required to prevent a second major outbreak of sars-cov-2 upon lifting quarantine in wuhan city","volume":"1","author":"Zhang","year":"2020"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.03.013","article-title":"Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity","author":"Garcia-Beltran","year":"2021","journal-title":"Cell."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.abg6105","article-title":"Neutralization of SARS-CoV-2 lineage B117 pseudovirus by BNT162b2 vaccine-elicited human sera","volume":"371","author":"Muik","year":"2021","journal-title":"Science."},{"key":"B41","doi-asserted-by":"publisher","first-page":"taab051","DOI":"10.1093\/jtm\/taab051","article-title":"Inactivated COVID-19 vaccine BBV152\/COVAXIN effectively neutralizes recently emerged B 1","volume":"28","author":"Sapkal","year":"2021","journal-title":"J Travel Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.chom.2021.03.002","article-title":"SARS-CoV-2 variant B","volume":"29","author":"Shen","year":"2021","journal-title":"Cell Host Microbe."},{"key":"B43","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1056\/NEJMc2104974","article-title":"Effectiveness of the BNT162b2 Covid-19 vaccine against the B","volume":"385","author":"Abu-Raddad","year":"2021","journal-title":"N Engl J Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.jinf.2021.04.038","article-title":"Effectiveness of BNT162b2 vaccine against the B","volume":"83","author":"Sansone","year":"2021","journal-title":"J Infect."},{"key":"B46","doi-asserted-by":"publisher","first-page":"n1088","DOI":"10.1136\/bmj.n1088","article-title":"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study","volume":"373","author":"Lopez Bernal","year":"2021","journal-title":"BMJ."},{"key":"B47","unstructured":"2021"},{"key":"B48","unstructured":"2021"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1101\/2021.11.14.21266318","article-title":"Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States","author":"Li","year":"2021"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cmi.2021.05.022","article-title":"Novel SARS-CoV-2 variants: the pandemics within the pandemic","volume":"27","author":"Boehm","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"B51","volume-title":"Features, Evaluation, and Treatment of Coronavirus (COVID-19)","author":"Cascella","year":"2021"},{"key":"B52","unstructured":"2021"},{"key":"B53","doi-asserted-by":"publisher","first-page":"100024","DOI":"10.1016\/j.xinn.2020.100024","article-title":"Achieving positive mental health and wellbeing on the COVID-19 frontline","volume":"1","author":"Khoo","year":"2020"},{"key":"B54","article-title":"Systemic approach in burnout prevention: a qualitative study on wellbeing of china deployed healthcare workers during COVID-19 pandemic","author":"Vicky","year":"2020","journal-title":"Front. Psychol"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2021.801763\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:44:22Z","timestamp":1641775462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2021.801763\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":54,"alternative-id":["10.3389\/fpubh.2021.801763"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2021.801763","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.06.24.21259370","asserted-by":"object"}]},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]},"article-number":"801763"}}